Anxiety suppression - PsychonautWiki

Anxiety suppression

Anxiety suppression (also known as anxiolysis or minimal sedation)[1] is medically recognized as a partial to complete suppression of a person’s ability to feel anxiety, general unease, and negative feelings of both psychological and physiological tension.[2] The experience of this effect may decrease anxiety-related behaviours such as restlessness, muscular tension,[3] rumination, and panic attacks. Complete anxiety suppression can produce feelings of extreme calmness and relaxation; however, it can also lead to undesirable outcomes when accompanied by other effects such as disinhibition or sedation.

It is most commonly induced under the influence of moderate dosages of anxiolytic compounds which primarily include GABAergic depressants,[4][5] such as benzodiazepines,[6] alcohol,[7] GHB,[8] and gabapentinoids[9]. However, it can also occur to a lesser extent under the influence of a large variety of other pharmacological classes which include but are not limited to cannabinoids,[10] dissociatives,[11] SSRIs, and opioids.


Medical use

  • Diazepam: Adults: Severe acute anxiety or agitation: 10 mg IV or IM injection.[12]

Psychoactive substances

Compounds within our psychoactive substance index which may cause this effect include:

... further results

Experience reports

Anecdotal reports which describe this effect within our experience index include:

See also

External links

References

  1. ↑ anxiolysis, National Cancer Institute 
  2. ↑ Gordon, Joshua A. (2002). "Anxiolytic drug targets: beyond the usual suspects". Journal of Clinical Investigation. 110 (7): 915–917. doi:10.1172/JCI0216846. ISSN 0021-9738. 
  3. ↑ Tyrer, P. (27 February 1988). "Prescribing psychotropic drugs in general practice". BMJ. 296 (6622): 588–589. doi:10.1136/bmj.296.6622.588. 
  4. ↑ Lydiard, R. B. (2003). "The role of GABA in anxiety disorders". The Journal of Clinical Psychiatry. 64 Suppl 3: 21–27. ISSN 0160-6689. 
  5. ↑ Gauthier, Isabelle; Nuss, Philippe (2015). "Anxiety disorders and GABA neurotransmission: a disturbance of modulation". Neuropsychiatric Disease and Treatment: 165. doi:10.2147/NDT.S58841. ISSN 1178-2021. 
  6. ↑ Wood, Alastair J.J.; Shader, Richard I.; Greenblatt, David J. (1993). "Use of Benzodiazepines in Anxiety Disorders". New England Journal of Medicine. 328 (19): 1398–1405. doi:10.1056/NEJM199305133281907. ISSN 0028-4793. 
  7. ↑ Smith, J. P., Randall, C. L. (2012). "Anxiety and alcohol use disorders: comorbidity and treatment considerations". Alcohol Research: Current Reviews. 34 (4): 414–431. ISSN 2168-3492. 
  8. ↑ Schmidt-Mutter, Catherine; Pain, Laure; Sandner, Guy; Gobaille, Serge; Maitre, Michel (1998). "The anxiolytic effect of γ-hydroxybutyrate in the elevated plus maze is reversed by the benzodiazepine receptor antagonist, flumazenil". European Journal of Pharmacology. 342 (1): 21–27. doi:10.1016/S0014-2999(97)01503-3. ISSN 0014-2999. 
  9. ↑ Pollack, Mark H.; Matthews, John; Scott, Erin L. (1998). "Gabapentin as a Potential Treatment for Anxiety Disorders". American Journal of Psychiatry. 155 (7): 992–993. doi:10.1176/ajp.155.7.992. ISSN 0002-953X. 
  10. ↑ Blessing, Esther M.; Steenkamp, Maria M.; Manzanares, Jorge; Marmar, Charles R. (2015). "Cannabidiol as a Potential Treatment for Anxiety Disorders". Neurotherapeutics. 12 (4): 825–836. doi:10.1007/s13311-015-0387-1. ISSN 1933-7213. 
  11. ↑ Irwin, Scott A.; Iglewicz, Alana (2010). "Oral Ketamine for the Rapid Treatment of Depression and Anxiety in Patients Receiving Hospice Care". Journal of Palliative Medicine. 13 (7): 903–908. doi:10.1089/jpm.2010.9808. ISSN 1096-6218. 
  12. ↑ (PDF) https://www.regionkronoberg.se/contentassets/7fd21479ae564476a1b8639e9519ede9/diazepam-hameln.pdf.  Missing or empty |title= (help)
Retrieved from ‘https://psychonautwiki.org/w/index.php?title=Anxiety_suppression&oldid=154886’